Elizabeth Yeu Lin sold $1.2M of TARS
Chief Medical Officer at Tarsus Pharmaceuticals, Inc.. 13,953 shares at an average of $87.50, traded Sep 4, 2026, filed Sep 9, 2026.
Score components
- +15RoleOfficer
- +25Trade size$1.2M at market
- +20Share of holdings soldSold 100% of holdings
- +15Cluster4 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001842190-26-000011, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 4, 2026 | SOpen-market sale Common Stock10b5-1 | -5,387 | $85.00 | $458k | 7,933 | 34 d ago |
| Sep 4, 2026 | SOpen-market sale Common Stock10b5-1 | -5,386 | $90.00 | $485k | 2,547 | 34 d ago |
| Sep 4, 2026 | SOpen-market sale Common Stockindirect: By Spouse's Roth IRA10b5-1 | -1,590 | $85.00 | $135k | 3,180 | 34 d ago |
| Sep 4, 2026 | SOpen-market sale Common Stockindirect: By Spouse's Roth IRA10b5-1 | -1,590 | $90.00 | $143k | 1,590 | 34 d ago |
Related signals
Other insiders at Tarsus Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 25Weak | Tarsus Pharmaceuticals, Inc. | William J Link Phd director | $980k 12,500 shares | -12% | |
| 44Moderate | Tarsus Pharmaceuticals, Inc. | Bobak R. Azamian President/CEO and Board Chair | $906k 10,000 shares | -1% | |
| 31Weak | Tarsus Pharmaceuticals, Inc. | Seshadri Neervannan Chief Operating Officer | $388k 4,564 shares | -5% | |
| 42Moderate | Tarsus Pharmaceuticals, Inc. | Bobak R. Azamian President/CEO and Board Chair | $801k 10,000 shares | -1% | |
| 44Moderate | Tarsus Pharmaceuticals, Inc. | Elizabeth Yeu Lin Chief Medical Officer | $898k 11,578 shares | -50% | |
| 40Moderate | Tarsus Pharmaceuticals, Inc. | Bobak R. Azamian President/CEO and Board Chair | $615k 10,000 shares | -1% | |
| 43Moderate | Tarsus Pharmaceuticals, Inc. | Jeffrey S Farrow See Remarks | $877k 14,396 shares | -20% | |
| 42Moderate | Tarsus Pharmaceuticals, Inc. | Katherine Goodrich director | $183k 2,954 shares | -57% | |
| 37Weak | Tarsus Pharmaceuticals, Inc. | William J Link Phd director | $776k 12,500 shares | -10% | |
| 27Weak | Tarsus Pharmaceuticals, Inc. | Seshadri Neervannan Chief Operating Officer | $200k 2,989 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.